# Sub-6A Baseline LLM Narratives — Per-Task Output

- **id_strategy**: `perfect_id`
- **n_tasks**: 14
- **errors**: 0
- **identification accuracy (mean)**: 100.00%
- **top1 strict rate**: 21.43%
- **top3 acceptance rate**: 21.43%
- **driver precision (mean)**: 0.539
- **driver recall (mean)**: 0.260
- **false noise rate (mean)**: 0.389
- **off-pathway mentions (mean)**: 6.57

---

## e2e_enrich_mammalian_RAMP_P_000000106_seed2068278441

- **GT pathway**: `Tyrosine metabolism`
- **predicted top pathway**: `purine metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.67 | **driver_recall**: 0.80 | **false_noise**: 0.33 | **off_pathway**: 12
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=9/9
- **claimed drivers**: ['FAD', 'Fumaric acid', 'Homocysteine', 'Ureidosuccinic acid', 'Caffeine', 'Tetrahydrobiopterin']
- **extracted pathways**: ['purine metabolism', 'methionine metabolism', 'pyrimidine biosynthesis', 'TCA cycle', 'Purine catabolism', 'IMP cycle', 'energy metabolism', 'transsulfuration cycle', 'one-carbon metabolism', 'novo biosynthesis', 'alkaloid metabolism', 'nucleotide metabolism']
- **off-pathway examples**: ['purine metabolism', 'methionine metabolism', 'pyrimidine biosynthesis', 'TCA cycle', 'Purine catabolism', 'IMP cycle', 'energy metabolism', 'transsulfuration cycle', 'one-carbon metabolism', 'novo biosynthesis', 'alkaloid metabolism', 'nucleotide metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006354915` | `VZCYOOQTPOCHFL` | `VZCYOOQTPOCHFL` | Fumaric acid | True |
| `sub6a-gnps-CCMSLIB00005464521` | `VWWQXMAJTJZDQX` | `VWWQXMAJTJZDQX` | FAD | True |
| `sub6a-gnps-MSBNK-mFam-MC21_000305` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-MoNA036446` | `RYYVLZVUVIJVGH` | `RYYVLZVUVIJVGH` | Caffeine | True |
| `sub6a-gnps-CCMSLIB00010137493` | `FNKQXYHWGSIFBK` | `FNKQXYHWGSIFBK` | Tetrahydrobiopterin | True |
| `sub6a-gnps-CCMSLIB00006356648` | `VZCYOOQTPOCHFL` | `VZCYOOQTPOCHFL` | Fumaric acid | True |
| `sub6a-gnps-CCMSLIB00005883932` | `FFFHZYDWPBMWHY` | `FFFHZYDWPBMWHY` | Homocysteine | True |
| `sub6a-gnps-CCMSLIB00010012777` | `RYYVLZVUVIJVGH` | `RYYVLZVUVIJVGH` | Caffeine | True |

### LLM Narrative

## Metabolomics Pathway Analysis

### 1. Most Likely Affected Pathways

The metabolite set strongly implicates **purine metabolism** and **one-carbon/methionine metabolism** as the primary affected pathways, with secondary connections to pyrimidine biosynthesis and the TCA cycle.

### 2. Key Driver Metabolites

| Metabolite | Pathway Role | Driver Significance |
|------------|--------------|---------------------|
| **FAD** | Purine catabolism (xanthine dehydrogenase cofactor) | Central node linking purine breakdown to redox state |
| **Fumaric acid** | Purine metabolism & TCA cycle | Connects AMP→IMP cycle with energy metabolism |
| **Homocysteine** | Methionine/transsulfuration cycle | Sensitive indicator of one-carbon metabolism status |
| **Ureidosuccinic acid** | Pyrimidine *de novo* biosynthesis | Direct intermediate in nucleotide synthesis |

**Caffeine** and **tetrahydrobiopterin** appear as secondary indicators—BH4 is a cofactor for aromatic amino acid hydroxylases, while caffeine reflects purine alkaloid metabolism.

### 3. Biological Significance

The co-elevation of **homocysteine** with **FAD** and **fumaric acid** suggests integrated stress on one-carbon metabolism and nucleotide flux. Elevated homocysteine indicates potential cardiovascular/neurological risk and disrupted methylation capacity. Changes in purine catabolism (reflected in FAD and fumaric acid) may alter cellular energy status and redox balance. Ureidosuccinic acid alterations suggest compensatory nucleotide synthesis.

### 4. Pathway Relationships

**Upstream:** GTP → BH4 synthesis; methionine → homocysteine generation  
**Downstream:** Homocysteine → cysteine (transsulfuration) or remethylation; purines → uric acid; pyrimidines → DNA/RNA synthesis  
**Cross-talk:** Fumaric acid links purine salvage to TCA cycle; FAD availability affects purine catabolism rates

The convergence on nucleotide metabolism and one-carbon pathways suggests a coordinated metabolic response, possibly reflecting oxidative stress or altered dietary/microbiome influences.

---

## e2e_enrich_mammalian_RAMP_P_000052705_seed2572336121

- **GT pathway**: `Statin inhibition of cholesterol production`
- **predicted top pathway**: `mevalonate pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 1.00 | **off_pathway**: 4
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=7/7
- **claimed drivers**: ['Squalene', 'Cyclic GMP', 'Aminoadipic acid', 'Indoleacetaldehyde']
- **extracted pathways**: ['mevalonate pathway', 'sterol biosynthesis', 'lysine catabolism', 'microbial pathway']
- **off-pathway examples**: ['mevalonate pathway', 'sterol biosynthesis', 'lysine catabolism', 'microbial pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006578098` | `YYGNTYWPHWGJRM` | `YYGNTYWPHWGJRM` | Squalene | True |
| `sub6a-gnps-CCMSLIB00006578103` | `YYGNTYWPHWGJRM` | `YYGNTYWPHWGJRM` | Squalene | True |
| `sub6a-gnps-MSBNK-mFam-MC22_000200` | `ZOOGRGPOEVQQDX` | `ZOOGRGPOEVQQDX` | Cyclic GMP | True |
| `sub6a-gnps-CCMSLIB00005884895` | `WHOOUMGHGSPMGR` | `WHOOUMGHGSPMGR` | Indoleacetaldehyde | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO003927` | `AQHHHDLHHXJYJD` | `AQHHHDLHHXJYJD` | Propranolol | True |
| `sub6a-gnps-MSBNK-mFam-MC23_000524` | `OYIFNHCXNCRBQI` | `OYIFNHCXNCRBQI` | Aminoadipic acid | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO003929` | `AQHHHDLHHXJYJD` | `AQHHHDLHHXJYJD` | Propranolol | True |

### LLM Narrative

## Pathway Analysis

Based on the metabolite identifiers provided, these five compounds span several distinct metabolic domains with limited direct overlap.

### 1. Most Likely Affected Pathways

- **Sterol/Cholesterol Biosynthesis** (via squalene)
- **cGMP-mediated Cell Signaling**
- **Tryptophan/Indole Metabolism** (gut microbiome-associated)
- **Lysine Degradation** (aminoadipic acid)
- **Exogenous Drug Exposure** (propranolol presence)

### 2. Key Drivers

**Squalene** is the committed precursor to the mevalonate pathway, making it a critical branchpoint for all downstream sterols. Its differential abundance directly implicates altered cholesterol/sterol biosynthesis. **Cyclic GMP** is a central second messenger produced by guanylyl cyclases and represents a signaling node rather than a pathway intermediate. **Aminoadipic acid** is downstream of lysine oxidation and intersects with mitochondrial function. **Indoleacetaldehyde** reflects microbial tryptophan conversion and indicates gut microbiome activity.

### 3. Biological Significance

Squalene changes may affect membrane fluidity, steroid hormone precursors, and coenzyme Q synthesis. cGMP alterations suggest modulation of vasodilatory, neuroprotective, or phototransduction pathways. Aminoadipic acid accumulation can indicate oxidative stress or disrupted mitochondrial lysine catabolism. Indoleacetaldehyde suggests altered microbiome-host metabolic cross-talk.

### 4. Upstream/Downstream Relationships

- **Squalene → Lanosterol → Cholesterol** (linear chain)
- **Tryptophan → Indole → Indoleacetaldehyde → Indole-3-acetic acid** (microbial pathway)
- **Lysine → Aminoadadipic semialdehyde → Aminoadipic acid**
- cGMP has no direct metabolic relationships with the other metabolites listed; it operates as a signaling molecule in cross-talk with other pathways.

**Note:** Propranolol is a pharmaceutical beta-blocker—its presence may indicate medication intake rather than endogenous metabolic dysregulation, which should be considered when interpreting results.

---

## e2e_enrich_mammalian_RAMP_P_000053157_seed2543740977

- **GT pathway**: `Selenium micronutrient network`
- **predicted top pathway**: `Eicosanoid biosynthesis`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 1.00 | **off_pathway**: 9
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=5/5
- **claimed drivers**: ['Guanabenz']
- **extracted pathways**: ['Eicosanoid biosynthesis', 'Hexosamine biosynthetic pathway', 'drug metabolism', 'Hexosamine pathway', 'GlcNAc signalling', 'Xenobiotic metabolism', 'inflammatory signalling', 'cellular signalling', 'distinct signalling']
- **off-pathway examples**: ['Eicosanoid biosynthesis', 'Hexosamine biosynthetic pathway', 'drug metabolism', 'Hexosamine pathway', 'GlcNAc signalling', 'Xenobiotic metabolism', 'inflammatory signalling', 'cellular signalling', 'distinct signalling']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00012060180` | `ZIOZYRSDNLNNNJ` | `ZIOZYRSDNLNNNJ` | 12(S)-HPETE | True |
| `sub6a-gnps-CCMSLIB00013046732` | `WDZVGELJXXEGPV` | `WDZVGELJXXEGPV` | Guanabenz | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO002280` | `FZLJPEPAYPUMMR` | `FZLJPEPAYPUMMR` | N-Acetyl-glucosamine 1-phosphate | True |
| `sub6a-gnps-CCMSLIB00012332249` | `WDZVGELJXXEGPV` | `WDZVGELJXXEGPV` | Guanabenz | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO002278` | `FZLJPEPAYPUMMR` | `FZLJPEPAYPUMMR` | N-Acetyl-glucosamine 1-phosphate | True |

### LLM Narrative

**1. Likely affected pathways**

- **Eicosanoid biosynthesis (arachidonic‑acid cascade)** – 12(S)‑HPETE is the direct product of 12‑lipoxygenase acting on arachidonic acid, so any change in its abundance points to altered lipoxygenase activity.
- **Hexosamine biosynthetic pathway** – N‑acetyl‑glucosamine 1‑phosphate is the first activated sugar in the route that generates UDP‑GlcNAc, the donor for protein O‑GlcNAcylation, N‑linked glycosylation and proteoglycan assembly.
- **Xenobiotic/drug metabolism** – Guanabenz is an exogenous α₂‑adrenergic agonist; its detection implies exposure to the compound and engagement of phase‑I/II drug‑metabolising enzymes.

**2. Key drivers in those pathways**

| Pathway | Primary driver | Reason |
|---|---|---|
| Eicosanoid biosynthesis | **12(S)‑HPETE** | Direct oxidation product of arachidonic acid by 12‑lipoxygenase; it sits at the branch point that leads to downstream inflammatory mediators (12‑HETE, hepoxilins). |
| Hexosamine pathway | **N‑acetyl‑glucosamine 1‑phosphate** | The earliest activated intermediate; its level controls flux to UDP‑GlcNAc, the central node for glycosylation and O‑GlcNAc signalling. |
| Xenobiotic metabolism | **Guanabenz** | Presence indicates that the experimental treatment includes this drug (or a structurally similar analogue), thus “driving” the drug‑handling arm of the metabolome. |

**3. Biological significance**

- **12(S)‑HPETE ↑** → heightened 12‑lipoxygenase activity, which can amplify inflammatory signalling, influence platelet aggregation and modulate neutrophil chemotaxis. It also reflects oxidative stress, as HPETEs are labile intermediates that are normally reduced to HETEs by peroxiredoxins/glutathione peroxidases.
- **N‑acetyl‑glucosamine 1‑phosphate ↑** → increased flux through the hexosamine pathway, raising UDP‑GlcNAc pools. This can boost O‑GlcNAcylation of nuclear and cytoplasmic proteins (impacting transcription, metabolism, and stress responses) and enhance N‑linked glycosylation of membrane receptors, affecting cellular signalling and protein folding capacity.
- **Guanabenz detection** → suggests central α₂‑adrenergic activation (reduced sympathetic tone, lowered blood pressure) and possibly activation of the unfolded‑protein response (guanabenz inhibits eIF2α phosphatase). These actions can cross‑talk with inflammatory and metabolic pathways.

**4. Up‑ and downstream relationships**

- **Up‑stream of 12(S)‑HPETE:** Phospholipase A₂ releases arachidonic acid; the enzyme 12‑lipoxygenase (ALOX12/ALOX15) adds molecular oxygen.  
- **Down‑stream:** 12(S)‑HPETE is rapidly reduced to 12‑HETE or metabolised to hepoxilins, both of which have distinct signalling roles.  
- **Up‑stream of N‑acetyl‑glucosamine 1‑phosphate:** Glucosamine‑6‑phosphate is acetylated by GNPNAT; downstream, UAP1 converts the monophosphate to UDP‑GlcNAc, which is then used by O‑GlcNAc transferase (OGT) and the oligosaccharyltransferase complex.  
- **For Guanabenz:** The compound is administered as a drug; phase‑I oxidation (CYP2C9/2C19) and phase‑II glucuronidation/sulfation are typical downstream transformations.

Together, the data suggest that the treatment pushes arachidonic‑acid oxidation and hexosamine‑driven glycosylation while delivering or mimicking a centrally acting sympatholytic agent, creating a coordinated shift in inflammatory, metabolic, and neuronal‑stress networks.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed269957960

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `Likely pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 1.00 | **driver_recall**: 0.40 | **false_noise**: 0.00 | **off_pathway**: 5
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=9/9
- **claimed drivers**: ['dCMP', 'Deoxycytidine']
- **extracted pathways**: ['Likely pathway', 'Pyrimidine metabolism', 'Flavonoid metabolism', 'pyrimidine degradation', 'glucose metabolism', 'accelerated catabolism', 'xenobiotic metabolism']
- **off-pathway examples**: ['Likely pathway', 'Flavonoid metabolism', 'glucose metabolism', 'accelerated catabolism', 'xenobiotic metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00005883798` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00000479749` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-CCMSLIB00010131208` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | Deoxycytidine | True |
| `sub6a-gnps-MoNA023871` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-MoNA033985` | `PGAVKCOVUIYSFO` | `PGAVKCOVUIYSFO` | Uridine triphosphate | True |
| `sub6a-gnps-CCMSLIB00005883801` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00005883754` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-CCMSLIB00012855498` | `IKIIZLYTISPENI` | `IKIIZLYTISPENI` | Baicalin | True |
| `sub6a-gnps-CCMSLIB00005720324` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |

### LLM Narrative

**Pathway inference**

The six metabolites fall into two functional clusters:

| Cluster | Metabolites | Likely pathway |
|---------|------------|----------------|
| **Pyrimidine‐related** | dCMP, Deoxycytidine, UMP, UTP, β‑alanine | **Pyrimidine metabolism** (synthesis, salvage, catabolism) |
| **Flavonoid/xenobiotic** | Baicalin | **Flavonoid metabolism / antioxidant response** |

The nucleosides and nucleotides (deoxy‑cytidine → dCMP and uridine → UMP → UTP) are classic intermediates of the pyrimidine salvage and de‑novo routes. β‑Alanine is a direct end‑product of uracil (and, to a lesser extent, cytosine) catabolism, so its presence signals that pyrimidine degradation is also altered.

**Key drivers**

- **dCMP** and **deoxycytidine** – upstream of the deoxy‑ribonucleotide pool, driving DNA synthesis/repair.
- **UMP / UTP** – central nodes that can be routed toward RNA synthesis, glycogen‑glucose metabolism (via UDP‑glucose) or glycosylation.
- **β‑Alanine** – a downstream marker of heightened uracil turnover.

**Biological significance**

A coordinated increase in deoxy‑cytidine/dCMP together with UMP/UTP suggests the treatment is stimulating pyrimidine salvage or demand for new nucleotides (e.g., proliferative or DNA‑repair response). Elevated β‑alanine indicates accelerated catabolism of uracil, possibly reflecting enhanced clearance of pyrimidine breakdown products or a shift toward carnosine synthesis (antioxidant dipeptide). Baicalin, a flavonoid glucuronide, is often detected after plant‑derived exposure; its presence may indicate an antioxidant/anti‑inflammatory modulation that could intersect with nucleotide‑related oxidative stress.

**Up‑stream / down‑stream relationships**

- **Deoxycytidine → dCMP** (phosphorylation by deoxycytidine kinase) – a classic upstream step that can limit the dNTP pool.
- **Uridine → UMP → UTP** – sequential phosphorylation; UTP can feed back to inhibit CPS‑II in de‑novo synthesis.
- **Uracil → β‑alanine** – catabolic cascade via dihydropyrimidine dehydrogenase, β‑ureidopropionase; thus β‑alanine is a downstream readout of pyrimidine breakdown.
- **Baicalin** – largely independent, but its glucuronide moiety may compete for UDP‑glucuronosyltransferase activity that also uses UDP‑glucose derived from the UMP pool, creating a subtle cross‑talk between nucleotide and xenobiotic metabolism.

Together, the data point to a treatment‑induced re‑wiring of pyrimidine metabolism (both synthetic and catabolic arms) accompanied by a possible antioxidant/xenobiotic response reflected by baicalin.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed2915906702

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `pyrimidine metabolism`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 0.80 | **driver_recall**: 0.80 | **false_noise**: 0.20 | **off_pathway**: 3
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=8/8
- **claimed drivers**: ['Ureidosuccinic acid', 'dCMP', 'Deoxycytidine', 'beta-Alanine', 'Ketamine']
- **extracted pathways**: ['pyrimidine metabolism', 'pyrimidine biosynthesis', 'novo pathway', 'carnosine metabolism', 'histidine metabolism', 'glycogen metabolism', 'salvage pathway', 'pyrimidine catabolism', 'The orotate pathway']
- **off-pathway examples**: ['novo pathway', 'salvage pathway', 'The orotate pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-MSBNK-Eawag-EA282606` | `YQEZLKZALYSWHR` | `YQEZLKZALYSWHR` | Ketamine | True |
| `sub6a-gnps-CCMSLIB00005720324` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00005883800` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00006115119` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-CCMSLIB00010142385` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | Deoxycytidine | True |
| `sub6a-gnps-MSBNK-mFam-MC22_000058` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-MoNA023871` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00000479750` | `PGAVKCOVUIYSFO` | `PGAVKCOVUIYSFO` | Uridine triphosphate | True |

### LLM Narrative

## Metabolic Pathway Analysis

### 1. Affected Pathways

The majority of these metabolites converge on **pyrimidine metabolism** and **pyrimidine biosynthesis** (specifically the orotate/de novo pathway). Additional connections exist to **carnosine metabolism** and **histidine metabolism** via beta-alanine.

### 2. Key Pathway Drivers

**Primary drivers:**
- **Ureidosuccinic acid** (carbamoyl aspartate) is the most upstream metabolite, representing the committed step where aspartate is combined with carbamoyl phosphate. This is the gatekeeper of de novo pyrimidine synthesis.
- **UTP** represents a major branch point, feeding into both RNA synthesis and glycogen metabolism (via UDP-glucose).

**Secondary drivers:**
- **dCMP** and **deoxycytidine** reflect the salvage pathway and DNA synthesis arm downstream.
- **beta-Alanine** links pyrimidine catabolism to histidine/carnosine metabolism.

**Outlier:**
- **Ketamine** is not an endogenous metabolite—it's the administered drug itself, serving as the experimental treatment.

### 3. Biological Significance

Coordinated changes in pyrimidine intermediates suggest altered nucleotide flux, potentially indicating: increased cell proliferation/division demands, DNA repair responses, or altered RNA synthesis. Ureidosuccinic acid elevation particularly suggests enhanced de novo synthesis capacity. If these represent downregulation, it may indicate impaired nucleotide availability affecting DNA replication.

### 4. Pathway Relationships

```
Carbamoyl phosphate + Aspartate
           ↓ (aspartate carbamoyltransferase)
    Ureidosuccinic acid
           ↓ → Dihydroorotate → Orotate → UMP
           ↓                         ↓
        beta-Alanine ← Orotic acid   UTP → RNA/glycogen
                                        ↓ (ribonucleotide reductase)
                                         dUDP → dCMP → Deoxycytidine
```

The orotate pathway (pyrimidine *de novo* synthesis) and the salvage pathway (via deoxycytidine → dCMP) appear interconnected, suggesting coordinated regulation of pyrimidine pools affecting both DNA synthesis and potentially carnosine-related antioxidant defenses.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed4051904823

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `pyrimidine metabolism`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 1.00 | **driver_recall**: 0.17 | **false_noise**: 0.00 | **off_pathway**: 7
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=11/11
- **claimed drivers**: ['Ureidosuccinic acid']
- **extracted pathways**: ['pyrimidine metabolism', 'salvage pathway', 'uracil degradation', 'Position in pathway', 'whole pathway', 'uracil catabolism', 'Signals increased degradation', 'pyrimidine biosynthesis', 'into catabolism', 'pyrimidine pathway']
- **off-pathway examples**: ['salvage pathway', 'uracil degradation', 'Position in pathway', 'whole pathway', 'uracil catabolism', 'Signals increased degradation', 'into catabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-MoNA033986` | `PGAVKCOVUIYSFO` | `PGAVKCOVUIYSFO` | Uridine triphosphate | True |
| `sub6a-gnps-CCMSLIB00005883757` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-CCMSLIB00000425559` | `OENHQHLEOONYIE` | `OENHQHLEOONYIE` | beta-Carotene | True |
| `sub6a-gnps-CCMSLIB00006115119` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-CCMSLIB00000577924` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | Deoxycytidine | True |
| `sub6a-gnps-CCMSLIB00005720346` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00000479750` | `PGAVKCOVUIYSFO` | `PGAVKCOVUIYSFO` | Uridine triphosphate | True |
| `sub6a-gnps-CCMSLIB00005883756` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-CCMSLIB00005720324` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00005883797` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |

### LLM Narrative

**Pathway inference**  
The clustering of uridine‑5′‑monophosphate (UMP), uridine‑triphosphate (UTP), carbamoyl‑aspartate (ureidosuccinic acid), deoxy‑cytidine and dCMP points strongly to **pyrimidine metabolism** – both the de‑novo biosynthetic route and the salvage pathway that feeds DNA synthesis. The simultaneous rise of β‑alanine signals that the **catabolism of uracil** (a pyrimidine base) is also accelerated, because uracil degradation yields β‑alanine. β‑Carotene does not belong to the pyrimidine network, but its elevation can be interpreted as a response to oxidative stress that often accompanies rapid nucleotide turnover.

**Key driver metabolites**  

| Metabolite | Position in pathway | Why it is a driver |
|------------|--------------------|--------------------|
| **Ureidosuccinic acid** (carbamoyl‑aspartate) | First committed step of de‑novo synthesis (aspartate transcarbamoylase) | Its increase indicates up‑regulation of the whole pathway upstream of UMP. |
| **UMP** | Direct precursor of UDP → UTP and of pyrimidine ribonucleotides | Central node linking de‑novo and salvage routes; high UMP fuels downstream nucleotide pools. |
| **UTP** | End‑product of the ribonucleotide branch and substrate for CTP and UDP‑glucose formation | Elevated UTP reflects overall flux toward nucleotide triphosphate synthesis. |
| **Deoxy‑cytidine / dCMP** | Salvage entry points for DNA precursors (converted to dCTP) | Their rise indicates activation of the DNA‑synthesis arm downstream of the ribonucleotide reduction step. |
| **β‑Alanine** | Product of uracil catabolism (via dihydropyrimidine dehydrogenase) | Signals increased degradation of pyrimidine bases, likely reflecting a compensatory outlet for excess uracil. |

**Biological significance**  
Co‑elevation of these metabolites suggests the treatment is stimulating **pyrimidine biosynthesis and salvage**, a hallmark of heightened proliferative or repair activity (e.g., immune activation, tumor cell growth, or response to DNA‑damaging agents). β‑Alanine accumulation further implies that excess pyrimidine bases are being shunted into catabolism rather than being stored. β‑Carotene may act as an antioxidant to neutralize reactive oxygen species generated during rapid metabolic turnover.

**Up‑stream / down‑stream relationships**  

- **Up‑stream:** The pathway starts with carbamoyl‑phosphate (from glutamine) and aspartate; the appearance of ureidosuccinic acid implies upstream enzymes (carbamoyl‑phosphate synthetase II, aspartate transcarbamoylase) are active.  
- **Mid‑stream:** UMP is phosphorylated to UDP then UTP (by nucleoside‑monophosphate kinases and NDPK).  
- **Down‑stream:** UTP can be converted to CTP or used for glycosylation; deoxy‑ribonucleotide formation proceeds via ribonucleotide reductase (converting CDP/UDP to dCDP/dUDP) leading to deoxy‑cytidine and dCMP, which are substrates for DNA polymerases.  
- **Catabolic offshoot:** Uracil produced from RNA turnover or pyrimidine breakdown is reduced to dihydrouracil and ultimately to β‑alanine, providing a sink for excess pyrimidines.

Thus, the data reflect a coordinated activation of the **de‑novo pyrimidine pathway** with downstream flux into **DNA precursors** and an auxiliary catabolic route, likely driven by increased cellular demand for nucleotides and a concomitant oxidative stress response.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed1809628705

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `Pyrimidine metabolism`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 1.00 | **driver_recall**: 0.33 | **false_noise**: 0.00 | **off_pathway**: 4
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=12/12
- **claimed drivers**: ['Ureidosuccinic acid', 'dCMP']
- **extracted pathways**: ['Pyrimidine metabolism', 'acid metabolism', 'Pyrimidine catabolism', 'eicosanoid metabolism', 'salvage pathway', 'pyrimidine pathway', 'lipoxygenase pathway']
- **off-pathway examples**: ['acid metabolism', 'eicosanoid metabolism', 'salvage pathway', 'lipoxygenase pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-CCMSLIB00005720338` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-MoNA024139` | `PGAVKCOVUIYSFO` | `PGAVKCOVUIYSFO` | Uridine triphosphate | True |
| `sub6a-gnps-MoNA024276` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-MSBNK-mFam-MC22_000058` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00012060180` | `ZIOZYRSDNLNNNJ` | `ZIOZYRSDNLNNNJ` | 12(S)-HPETE | True |
| `sub6a-gnps-CCMSLIB00005883801` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00005883904` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | Deoxycytidine | True |
| `sub6a-gnps-MoNA023877` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00013023834` | `XZWYZXLIPXDOLR` | `XZWYZXLIPXDOLR` | 1,1-Dimethylbiguanide | True |
| `sub6a-gnps-MoNA023871` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00005883906` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | Deoxycytidine | True |

### LLM Narrative

## Pathway Analysis

### 1. Affected Metabolic Pathways

**Pyrimidine metabolism** is the most clearly affected pathway, evidenced by five metabolites: ureidosuccinic acid (N-carbamoyl-L-aspartate), UMP, UTP, dCMP, and deoxycytidine. These represent de novo synthesis intermediates (ureidosuccinic acid → orotate → UMP) and downstream nucleotide products.

**Lipoxygenase-mediated arachidonic acid metabolism** is implicated by 12(S)-HPETE accumulation.

**Pyrimidine catabolism** is suggested by elevated β-alanine, which is generated when uracil undergoes ring opening.

The presence of metformin (1,1-dimethylbiguanide) is interesting—this is an AMPK activator that suppresses hepatic gluconeogenesis, potentially linking to broader metabolic regulation.

### 2. Key Pathway Drivers

- **Ureidosuccinic acid** is the committed early step in *de novo* pyrimidine synthesis (aspartate transcarbamoylase reaction).
- **dCMP** sits at the junction of pyrimidine salvage and DNA synthesis, directly connecting to deoxyribonucleotide pools.

### 3. Biological Significance

Multiple pyrimidine intermediates suggest either increased nucleotide demand (cell proliferation, repair) or feedback disruption. Elevated 12(S)-HPETE indicates shifted eicosanoid metabolism toward lipoxygenase products, affecting inflammation resolution. β-alanine elevation links pyrimidine catabolism to肌肉酸碱平衡 and carnosine synthesis. Metformin presence may indicate metabolic stress or experimental design involving diabetic models.

### 4. Pathway Relationships

Ureidosuccinic acid → UMP → UTP represents sequential phosphorylation. dCMP and deoxycytidine occupy the salvage pathway branch. β-alanine represents the downstream catabolic terminus of uracil. The coordinated elevation across these nodes suggests broad pyrimidine pathway activation rather than isolated blockages.

---
**Summary**: This pattern most strongly implicates *pyrimidine metabolism* with concurrent *lipoxygenase pathway* modulation. The co-occurrence with metformin suggests metabolic stress or therapeutic intervention affecting nucleotide homeostasis.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed3100819975

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `nucleotide biosynthesis`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 1.00 | **driver_recall**: 0.50 | **false_noise**: 0.00 | **off_pathway**: 3
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=7/7
- **claimed drivers**: ['Ureidosuccinic acid', 'Deoxycytidine', 'dCMP']
- **extracted pathways**: ['nucleotide biosynthesis', 'pyrimidine catabolism', 'uracil degradation', 'pyrimidine biosynthesis', 'pyrimidine metabolism', 'muscle metabolism', 'Pyrimidine degradation', 'salvage pathway']
- **off-pathway examples**: ['uracil degradation', 'muscle metabolism', 'salvage pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-MoNA024139` | `PGAVKCOVUIYSFO` | `PGAVKCOVUIYSFO` | Uridine triphosphate | True |
| `sub6a-gnps-CCMSLIB00006120479` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | Deoxycytidine | True |
| `sub6a-gnps-MoNA023877` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00003134725` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-CCMSLIB00005883801` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | Ureidosuccinic acid | True |
| `sub6a-gnps-MoNA024285` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | dCMP | True |

### LLM Narrative

## Pathway Analysis

### 1. Most Affected Pathway: **Pyrimidine Metabolism**

The strongest signal comes from pyrimidine-related metabolites:
- **UMP** and **UTP** are direct intermediates in pyrimidine nucleotide biosynthesis
- **Deoxycytidine** and **dCMP** feed into pyrimidine salvage for DNA synthesis
- **Ureidosuccinic acid** (orotic acid) is a classic intermediate in *de novo* pyrimidine synthesis
- **β-Alanine** connects to pyrimidine catabolism, as uracil degradation generates β-alanine

### 2. Key Pathway Drivers

The most central drivers are **ureidosuccinic acid** (orotic acid) and **UMP**, which sit at the committed step of *de novo* pyrimidine biosynthesis. Elevated **UTP** indicates increased flux toward nucleotide triphosphate pools. The **deoxycytidine/dCMP** pair suggests enhanced pyrimidine salvage, particularly for DNA precursor supply.

### 3. Biological Significance

Coordinated elevation of these metabolites suggests increased **nucleotide biosynthetic demand**. This is consistent with:
- Enhanced cell proliferation or tissue regeneration
- Active DNA replication/repair
- Immune cell activation (requiring nucleotide supply)

β-Alanine elevation is particularly noteworthy as it links pyrimidine metabolism to **coenzyme A biosynthesis** and neurotransmitter/muscle metabolism, suggesting broader metabolic reprogramming beyond nucleotide pools.

### 4. Upstream/Downstream Relationships

```
Ureidosuccinic acid → UMP → UDP → UTP
                              ↓
Deoxycytidine → dCMP → dCTP → DNA synthesis

β-Alanine ← Uracil ← Pyrimidine degradation
```

The elevated orotic acid and pyrimidine nucleotides suggest **upstream activation of *de novo* synthesis** rather than salvage pathway reliance. This implies the treatment triggers biosynthetic demand rather than simply recycling existing nucleotides.

---

## e2e_enrich_mammalian_RAMP_P_000025712_seed4052145624

- **GT pathway**: `Sulindac Action Pathway`
- **predicted top pathway**: `methionine metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 1.00 | **off_pathway**: 6
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=12/12
- **claimed drivers**: ['Sulindac', 'Deoxycorticosterone']
- **extracted pathways**: ['methionine metabolism', 'AA metabolism', 'Mineralocorticoid biosynthesis', 'thromboxane signaling', 'leukotriene biosynthesis', 'methionine cycle', 'hormone biosynthesis']
- **off-pathway examples**: ['methionine metabolism', 'AA metabolism', 'Mineralocorticoid biosynthesis', 'thromboxane signaling', 'methionine cycle', 'hormone biosynthesis']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00012060180` | `ZIOZYRSDNLNNNJ` | `ZIOZYRSDNLNNNJ` | 12(S)-HPETE | True |
| `sub6a-gnps-CCMSLIB00011428388` | `JNUUNUQHXIOFDA` | `JNUUNUQHXIOFDA` | 5(S)-Hydroperoxyeicosatetraenoic acid | True |
| `sub6a-gnps-CCMSLIB00011428462` | `YIBNHAJFJUQSRA` | `YIBNHAJFJUQSRA` | Prostaglandin H2 | True |
| `sub6a-gnps-MSBNK-ACES_SU-AS000616` | `ZESRJSPZRDMNHY` | `ZESRJSPZRDMNHY` | Deoxycorticosterone | True |
| `sub6a-gnps-CCMSLIB00003135953` | `ZESRJSPZRDMNHY` | `ZESRJSPZRDMNHY` | Deoxycorticosterone | True |
| `sub6a-gnps-CCMSLIB00016270605` | `MLKXDPUZXIRXEP` | `MLKXDPUZXIRXEP` | Sulindac | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000565` | `XNRNNGPBEPRNAR` | `XNRNNGPBEPRNAR` | Thromboxane B2 | True |
| `sub6a-gnps-CCMSLIB00011428290` | `ZIOZYRSDNLNNNJ` | `ZIOZYRSDNLNNNJ` | 12(S)-HPETE | True |
| `sub6a-gnps-CCMSLIB00006116167` | `MLKXDPUZXIRXEP` | `MLKXDPUZXIRXEP` | Sulindac | True |
| `sub6a-gnps-CCMSLIB00012060235` | `QQUFCXFFOZDXLA` | `QQUFCXFFOZDXLA` | 8(S)-HPETE | True |
| `sub6a-gnps-CCMSLIB00013031181` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000566` | `XNRNNGPBEPRNAR` | `XNRNNGPBEPRNAR` | Thromboxane B2 | True |

### LLM Narrative

**Pathway inference**

The metabolite list points strongly to **arachidonic‑acid (AA) cascade** remodeling and, to a lesser extent, to **adrenal steroidogenesis** and **one‑carbon/methionine metabolism**.

| Metabolite | Dominant route |
|------------|-----------------|
| 5(S)‑HPETE, 8(S)‑HPETE, 12(S)‑HPETE | Lipoxygenase (LOX) branch of AA metabolism |
| Prostaglandin H2 (PGH2) | Cyclo‑oxygenase (COX) branch of AA metabolism |
| Thromboxane B2 (TXB2) | Down‑stream product of PGH2 via TXA2 → TXB2 |
| Sulindac | Exogenous non‑selective COX inhibitor (active sulfide) |
| Deoxycorticosterone (DOC) | Mineralocorticoid biosynthesis (up‑stream of aldosterone) |
| L‑Methionine | Core of the methionine‑cycle, linking to glutathione synthesis and methylation |

**Key drivers**

- **PGH2** is the central COX‑derived intermediate; its abundance indicates residual COX activity despite sulindac.
- **TXB2** is the stable surrogate of the pro‑thrombotic mediator TXA2, reflecting downstream thromboxane signaling.
- The three **HPETEs** are the primary LOX‑derived drivers; 5‑HPETE initiates leukotriene biosynthesis, while 12‑ and 8‑HPETE feed the 12‑/8‑HETE pathways.
- **Sulindac** acts upstream by blocking COX, shunting AA toward LOX enzymes; its detection confirms drug exposure.

**Biological significance**

- A relative rise in HPETEs with continued PGH2/TXB2 suggests the treatment **shunts AA metabolism from the COX to the LOX branch**, a hallmark of NSAID‑induced metabolic diversion.
- Increased TXB2 (or its ratio to other prostaglandins) influences **platelet aggregation, vasoconstriction, and vascular inflammation**.
- Elevated DOC hints at **adrenal steroidogenic perturbation**, potentially reflecting stress‑axis or mineralocorticoid‑target‑organ effects of the intervention.
- Higher L‑Methionine can be a cellular response to **oxidative stress** generated by hydroperoxy‑eicosanoids, feeding into glutathione synthesis and methylation pathways.

**Up‑stream / down‑stream relationships**

- **AA (up‑stream)** → **PGH2 (COX)** → TXA2 → **TXB2 (down‑stream)**, or → various prostaglandins.
- **AA (up‑stream)** → **5‑/8‑/12‑HPETE (LOX)** → downstream leukotrienes/HETEs.
- **Sulindac** inhibits the COX step, pushing flux toward the LOX arm.
- **DOC** is up‑stream of aldosterone, regulated by CYP11B2; its change may reflect endocrine modulation.
- **L‑Methionine** feeds the methionine cycle, providing SAM for methylation and cysteine for GSH synthesis, linking oxidative‑stress handling to the eicosanoid burst.

In summary, the data most strongly implicate **remodeling of the AA cascade** (COX vs. LOX) as the primary pathway affected, with secondary disturbances in **steroid hormone biosynthesis** and **methionine‑dependent antioxidant capacity**.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed1549320213

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `energy metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 1.00 | **driver_recall**: 0.12 | **false_noise**: 0.00 | **off_pathway**: 10
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=8/8
- **claimed drivers**: ['Pyruvic acid']
- **extracted pathways**: ['energy metabolism', 'TCA cycle', 'acid metabolism', 'methyl cycle', 'sulfuration pathway', 'Polyamine biosynthesis', 'SAM cycle', 'polyamine pathway', 'mediated signaling', 'carbon metabolism']
- **off-pathway examples**: ['energy metabolism', 'TCA cycle', 'acid metabolism', 'methyl cycle', 'sulfuration pathway', 'Polyamine biosynthesis', 'SAM cycle', 'polyamine pathway', 'mediated signaling', 'carbon metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006553841` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00006676843` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00010141258` | `XZWYZXLIPXDOLR` | `XZWYZXLIPXDOLR` | 1,1-Dimethylbiguanide | True |
| `sub6a-gnps-CCMSLIB00013576636` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-VF-NPL-QEHF028146` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |
| `sub6a-gnps-CCMSLIB00005883641` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-CCMSLIB00013576635` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-CCMSLIB00005883645` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |

### LLM Narrative

**1. Likely affected pathways**

- **Central‐carbon/energy metabolism** – pyruvic acid sits at the junction of glycolysis, gluconeogenesis and the TCA cycle.  
- **Gluconeogenesis regulation** – 1,1‑dimethylbiguanide (a biguanide, pharmacologically similar to metformin) is a known inhibitor of mitochondrial complex I and a potent activator of AMPK, which represses hepatic glucose production.  
- **One‑carbon and sulfur‑amino‑acid metabolism** – L‑methionine feeds the methionine‑SAM‑methyl cycle and the trans‑sulfuration pathway that generates cysteine and subsequently glutathione.  
- **Polyamine biosynthesis** – putrescine is the first polyamine formed from ornithine (via ornithine decarboxylase) and is linked to the aminopropyl‑donor supply from decarboxylated SAM.  
- **Redox/antioxidant capacity** – L‑cysteine is the rate‑limiting precursor for glutathione and for hydrogen‑sulfide (H₂S) synthesis.

**2. Key drivers in those pathways**

| Metabolite | Primary role in the pathway |
|------------|------------------------------|
| **Pyruvic acid** | Central node linking glycolysis → TCA cycle and a substrate for gluconeogenesis. |
| **1,1‑Dimethylbiguanide** | Exogenous modulator that blocks hepatic gluconeogenesis and stimulates AMPK, thereby reshaping pyruvate utilization. |
| **L‑Methionine** | Entry point for the methionine‑SAM cycle; provides the methyl group needed for polyamine aminopropylation. |
| **L‑Cysteine** | End‑product of the trans‑sulfuration branch; essential for glutathione and H₂S production. |
| **Putrescine** | First product of the polyamine pathway; reflects flux through ornithine decarboxylase. |

**3. Biological significance**

- **Energy re‑programming** – Altered pyruvate levels together with biguanide action suggest a shift from oxidative phosphorylation toward glycolysis or a reduction in gluconeogenic flux, a hallmark of AMPK‑activating treatments.  
- **Redox balance** – Coordinated changes in methionine → cysteine → glutathione indicate modulation of the antioxidant system; decreased cysteine could imply reduced glutathione synthesis and heightened oxidative stress.  
- **Polyamine‑mediated signaling** – Perturbed putrescine reflects altered cell‑proliferation and differentiation cues, since polyamines are essential for nucleic‑acid stabilization and growth.  
- **Inter‑connected one‑carbon metabolism** – Methionine‑SAM is required for both methylation reactions and for generating the aminopropyl donor (dcSAM) used in polyamine synthesis; therefore, the observed changes hint at a coordinated remodeling of methylation and growth‑control pathways.

**4. Up‑/down‑stream relationships**

- **Up‑stream**: 1,1‑dimethylbiguanide → AMPK activation → inhibition of hepatic gluconeogenesis → accumulation (or altered turnover) of pyruvate.  
- **Mid‑stream**: Pyruvate can be transaminated to alanine or carboxylated to oxaloacetate, linking it to amino‑acid metabolism.  
- **Branch point**: Methionine → SAM → methyl‑transfer → homocysteine → cysteine → glutathione/H₂S (down‑stream).  
- **Cross‑talk**: SAM also donates an aminopropyl group to putrescine to form spermidine/spermine, so altered methionine flux can affect polyamine biosynthesis.  
- **Down‑stream**: Elevated putrescine may influence cell‑cycle progression, while reduced cysteine compromises the cellular antioxidant barrier, potentially amplifying stress signals from metformin‑induced mitochondrial inhibition.

Taken together, the differential abundance pattern points to a coordinated reshaping of energy metabolism, one‑carbon/sulfur chemistry, and polyamine homeostasis, likely driven by the pharmacological action of the biguanide and reflected in downstream redox and proliferative pathways.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed2917579066

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `Polyamine biosynthesis`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 1.00 | **off_pathway**: 7
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=7/7
- **claimed drivers**: ['Milrinone']
- **extracted pathways**: ['Polyamine biosynthesis', 'polyamine metabolism', 'stress signalling', 'TCA cycle', 'dependent signalling', 'cAMP signalling', 'protective signalling']
- **off-pathway examples**: ['Polyamine biosynthesis', 'polyamine metabolism', 'stress signalling', 'TCA cycle', 'dependent signalling', 'cAMP signalling', 'protective signalling']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00012301293` | `PZRHRDRVRGEVNW` | `PZRHRDRVRGEVNW` | Milrinone | True |
| `sub6a-gnps-CCMSLIB00013576274` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-CCMSLIB00006553873` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005884067` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |
| `sub6a-gnps-CCMSLIB00006676837` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00013007994` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-VF-NPL-QEHF028142` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |

### LLM Narrative

**Likely pathways**

1. **Methionine ↔ Cysteine (trans‑sulfuration) pathway** – L‑Methionine feeds into the cycle that generates L‑Cysteine through homocysteine and cystathionine. Changes in both metabolites point to altered one‑carbon/methylation and downstream antioxidant capacity.

2. **Polyamine biosynthesis** – Putrescine is the first polyamine produced from ornithine (via ornithine‑decarboxylase). Its differential abundance flags shifts in polyamine metabolism that affect cell‑proliferation, protein synthesis and oxidative‑stress signalling.

3. **Central carbon / glycolysis‑TCA node** – Pyruvic acid sits at the hub where glycolysis, gluconeogenesis and the TCA cycle intersect. Its change can reflect either increased glycolytic flux or a mitochondrial upstream block.

4. **cAMP‑dependent signalling (pharmacological effect)** – Milrinone is a phosphodiesterase‑3 inhibitor. Its presence indicates pharmacologic PDE3 blockade, which raises cellular cAMP, activating protein‑kinase‑A and stimulating glycogenolysis/lipolysis, thereby raising downstream glycolytic intermediates such as pyruvate.

**Key drivers**

- **Milrinone** – master trigger of the cAMP‑PKA cascade that can drive the observed rise in pyruvate.  
- **L‑Methionine** – upstream substrate that sets the flux through the trans‑sulfuration route; its level dictates how much cysteine can be generated.  
- **L‑Cysteine** – downstream driver of glutathione synthesis and H₂S signalling, linking redox balance to the methionine‑derived pool.  
- **Pyruvate** – central node that integrates glycolytic input with TCA‑cycle flux and amino‑acid anaplerosis.  
- **Putrescine** – early polyamine that feeds into the synthesis of spermidine/spermine, influencing growth and stress‑response pathways.

**Biological significance**

- **Redox and detoxification** – up‑regulated cysteine supports greater glutathione production, a cellular safeguard against oxidative stress.  
- **Methylation capacity** – altered methionine flux can affect SAM‑dependent methylations, impacting DNA, proteins and lipids.  
- **Energy re‑programming** – increased pyruvate suggests heightened glycolytic or glycogen‑olytic activity, consistent with Milrinone‑induced cAMP signalling.  
- **Polyamine‑driven growth** – changes in putrescine signal shifts in proliferative or protective signalling.

**Up‑/down‑stream relationships**

- **Methionine → homocysteine → cystathionine → cysteine**; cysteine → glutathione (down‑stream).  
- **Pyruvate** is downstream of glycolysis and upstream of acetyl‑CoA/TCA.  
- **Putrescine** is downstream of ornithine and upstream of larger polyamines (spermidine, spermine).  
- **Milrinone** acts upstream of cAMP, which can enhance glycogenolysis → glucose → pyruvate, linking drug action to the central‑carbon node.

Collectively, the pattern suggests a coordinated metabolic shift: a pharmacologic increase in cAMP (Milrinone) boosts glycolytic flux (pyruvate), while the methionine‑cysteine axis is remodeled to support methylation and antioxidant defenses, and polyamine metabolism is re‑tuned, possibly reflecting adaptive responses to the drug‑induced energy surge and oxidative challenge.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed3265338497

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `purine catabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.33 | **driver_recall**: 0.14 | **false_noise**: 0.67 | **off_pathway**: 7
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=9/9
- **claimed drivers**: ['Uric acid', 'L-Cysteine', '6-Methylmercaptopurine']
- **extracted pathways**: ['purine catabolism', 'purine metabolism', 'Secondary pathway', 'Transsulfuration pathway', 'methionine cycle', 'one-carbon metabolism', 'polyamine biosynthesis', 'thiopurine pathway', 'purine degradation', 'methionine-homocysteine metabolism', 'cellular signaling']
- **off-pathway examples**: ['purine catabolism', 'Secondary pathway', 'Transsulfuration pathway', 'polyamine biosynthesis', 'thiopurine pathway', 'purine degradation', 'cellular signaling']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00005884067` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO001471` | `UIJIQXGRFSPYQW` | `UIJIQXGRFSPYQW` | 6-Methylmercaptopurine | True |
| `sub6a-gnps-CCMSLIB00005883640` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-MoNA036248` | `ALYNCZNDIQEVRV` | `ALYNCZNDIQEVRV` | p-Aminobenzoic acid | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000887` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-CCMSLIB00005883531` | `ALYNCZNDIQEVRV` | `ALYNCZNDIQEVRV` | p-Aminobenzoic acid | True |
| `sub6a-gnps-CCMSLIB00006553841` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005883632` | `LEHOTFFKMJEONL` | `LEHOTFFKMJEONL` | Uric acid | True |
| `sub6a-gnps-CCMSLIB00005884065` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |

### LLM Narrative

# Pathway Analysis of Differentially Abundant Metabolites

## 1. Most Likely Affected Pathways

**Primary pathway: Purine Metabolism**
- Uric acid (endpoint of purine catabolism)
- 6-Methylmercaptopurine (thiopurine analog related to purine metabolism)
- Both elevation suggests altered purine turnover

**Secondary pathway: Sulfur Amino Acid Metabolism (Transsulfuration pathway)**
- L-Cysteine (central node linking methionine cycle to glutathione synthesis)
- p-Aminobenzoic acid (involved in folate/one-carbon metabolism)
- Putrescine (polyamine biosynthesis from ornithine)

**Tertiary: Central Carbon/Energy Metabolism**
- Pyruvic acid (glycolysis-TCA interface, connects multiple pathways)

## 2. Key Driver Metabolites

- **Uric acid**: Master regulator endpoint reflecting purine flux
- **L-Cysteine**: Pivot point controlling glutathione synthesis and redox balance
- **6-Methylmercaptopurine**: Direct indicator of thiopurine pathway activity

## 3. Biological Significance

Elevated uric acid combined with 6-methylmercaptopurine accumulation suggests either increased purine degradation or disrupted downstream processing. The cysteine alteration may reflect antioxidant response (glutathione demand) or altered methionine-homocysteine metabolism. Putrescine elevation indicates shifts in polyamine homeostasis, affecting cell proliferation and stress responses.

## 4. Upstream/Downstream Relationships

- Purine metabolism → xanthine oxidase → uric acid (upstream: adenine/guanine nucleotides)
- Methionine → cystathionine → cysteine → glutathione (transsulfuration pathway)
- Ornithine → putrescine → spermidine → spermine (polyamine biosynthesis)

These pathways intersect through one-carbon metabolism and methylation reactions, potentially affecting DNA synthesis, antioxidant capacity, and cellular signaling under treatment conditions.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed1221928389

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `kynurenine pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 9
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=12/12
- **claimed drivers**: []
- **extracted pathways**: ['kynurenine pathway', 'acid pathway', 'Polyamine biosynthesis', 'TCA cycle', 'acid catabolism', 'tryptophan metabolism', 'energy metabolism', 'growth signaling', 'acid metabolism']
- **off-pathway examples**: ['kynurenine pathway', 'acid pathway', 'Polyamine biosynthesis', 'TCA cycle', 'acid catabolism', 'tryptophan metabolism', 'energy metabolism', 'growth signaling', 'acid metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006581466` | `KBPHJBAIARWVSC` | `KBPHJBAIARWVSC` | Lutein | True |
| `sub6a-gnps-CCMSLIB00005884063` | `VYFYYTLLBUKUHU` | `VYFYYTLLBUKUHU` | Dopamine | True |
| `sub6a-gnps-MoNA033659` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-CCMSLIB00005883641` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000887` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-VF-NPL-QTOF009478` | `GJAWHXHKYYXBSV` | `GJAWHXHKYYXBSV` | Quinolinic acid | True |
| `sub6a-gnps-CCMSLIB00006553889` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005884060` | `VYFYYTLLBUKUHU` | `VYFYYTLLBUKUHU` | Dopamine | True |
| `sub6a-gnps-CCMSLIB00005885000` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-VF-NPL-QEHF028147` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |
| `sub6a-gnps-CCMSLIB00006553841` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005884011` | `GJAWHXHKYYXBSV` | `GJAWHXHKYYXBSV` | Quinolinic acid | True |

### LLM Narrative

**1. Likely affected pathways**  
- **Tryptophan → kynurenine → quinolinic acid** (neuro‑active branch of the kynurenine pathway).  
- **Tyrosine → catecholamine synthesis → dopamine**.  
- **Sulfur‑amino‑acid pathway**: L‑methionine → L‑cysteine → glutathione.  
- **Polyamine biosynthesis**: arginine → ornithine → putrescine.  
- **Central energy node**: glycolysis → pyruvate, linking to the TCA cycle.  
- **Carotenoid antioxidant route**: lutein (xanthophyll) as a scavenger of reactive oxygen species.

**2. Key driver metabolites**  
- **Pyruvate** – sits at the crossroads of glycolysis, amino‑acid catabolism, and the TCA cycle, so any change reverberates through many downstream processes.  
- **Quinolinic acid** – a downstream neurotoxic metabolite that reflects activation of the kynurenine branch of tryptophan metabolism.  
- **L‑Methionine → L‑Cysteine** – the trans‑sulfuration gateway to glutathione; depletion of either shifts the redox balance.  
- **Dopamine** – a central neurotransmitter whose altered level signals changes in catecholamine synthesis.  
- **Putrescine** – the first polyamine produced from ornithine, influencing cell‑proliferation and stress‑response pathways.  
- **Lutein** – a dietary antioxidant whose presence indicates exposure to oxidative challenge.

**3. Biological significance**  
Changes in this set suggest a coordinated shift in (i) **oxidative stress** (reduced cysteine → glutathione, altered lutein), (ii) **neuroinflammation** (elevated quinolinic acid, perturbed dopamine), (iii) **energy metabolism** (pyruvate flux), and (iv) **cell‑growth signaling** (polyamine turnover). Such multi‑pathway alterations are typical in neuro‑degenerative disorders, cancer, or metabolic syndrome.

**4. Up‑stream/down‑stream relationships**  
- **Methionine** is upstream of **cysteine**, which is upstream of **glutathione**.  
- **Arginine → ornithine → putrescine** forms a linear downstream chain.  
- **Tryptophan → quinolinic acid** is downstream of the kynurenine pathway.  
- **Tyrosine → dopamine** occupies a downstream position in the catecholamine route.  
- **Pyruvate** receives input from glycolysis and amino‑acid catabolism, and feeds into the TCA cycle, placing it downstream of many catabolic routes and upstream of energy‑yielding pathways.  
- **Lutein** acts upstream of oxidative‑stress responses by scavenging radicals; its depletion can downstream amplify damage.

Together, these relationships illustrate a network in which perturbations of upstream amino‑acid metabolism (methionine, cysteine) cascade into downstream neurochemical (quinolinic acid, dopamine) and polyamine (putrescine) effects, while pyruvate and lutein connect the metabolic hub to energy balance and antioxidant capacity.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed2332602456

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `transsulfuration pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.75 | **driver_recall**: 0.38 | **false_noise**: 0.25 | **off_pathway**: 6
- **identification**: strategy=`perfect_id`, id_acc=1.0, n_id=12/12
- **claimed drivers**: ['L-Cysteine', 'L-Methionine', 'Pyruvic acid', 'L-Glutamic acid']
- **extracted pathways**: ['transsulfuration pathway', 'acid pathway', 'acid metabolism', 'nitrogen metabolism', 'TCA cycle', 'tyrosine catabolism']
- **off-pathway examples**: ['transsulfuration pathway', 'acid pathway', 'acid metabolism', 'nitrogen metabolism', 'TCA cycle', 'tyrosine catabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00013031139` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-CCMSLIB00005884071` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |
| `sub6a-gnps-CCMSLIB00006676829` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00006112717` | `WHUUTDBJXJRKMK` | `WHUUTDBJXJRKMK` | L-Glutamic acid | True |
| `sub6a-gnps-CCMSLIB00006676047` | `IGMNYECMUMZDDF` | `IGMNYECMUMZDDF` | Homogentisic acid | True |
| `sub6a-gnps-CCMSLIB00013576274` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-Methionine | True |
| `sub6a-gnps-VF-NPL-QEHF028154` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | Putrescine | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000887` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-CCMSLIB00006126553` | `SBJKKFFYIZUCET` | `SBJKKFFYIZUCET` | Dehydroascorbic acid | True |
| `sub6a-gnps-CCMSLIB00006553873` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00006673216` | `IGMNYECMUMZDDF` | `IGMNYECMUMZDDF` | Homogentisic acid | True |
| `sub6a-gnps-CCMSLIB00006126550` | `SBJKKFFYIZUCET` | `SBJKKFFYIZUCET` | Dehydroascorbic acid | True |

### LLM Narrative

## Pathway Analysis

### 1. Most Likely Affected Pathways

**Sulfur Amino Acid Metabolism / Transsulfuration Pathway** is the most prominent pathway suggested by these metabolites. L-Methionine and L-Cysteine are directly connected through the transsulfuration pathway, where homocysteine (derived from methionine) is converted to cysteine via cystathionine. The presence of both metabolites indicates potential disruption in this pathway.

**Glutathione Synthesis** is strongly implied, as L-Cysteine is the rate-limiting precursor and L-Glutamic acid provides the glutamate component of glutathione. Combined with dehydroascorbic acid (the oxidized form of vitamin C, an important antioxidant partner), this suggests oxidative stress response involvement.

**Polyamine Biosynthesis** is indicated by elevated putrescine, which is synthesized directly from ornithine via ornithine decarboxylase.

### 2. Key Drivers

- **L-Cysteine** and **L-Methionine** are primary drivers of the sulfur amino acid pathway
- **Pyruvic acid** acts as a central hub connecting amino acid metabolism to energy production
- **L-Glutamic acid** links nitrogen metabolism, glutathione synthesis, and TCA cycle anaplerosis

### 3. Biological Significance

Changes in sulfur amino acid metabolism suggest altered methylation capacity (affecting epigenetic regulation) and reduced glutathione synthesis, indicating **oxidative stress** or compromised antioxidant defenses. Elevated putrescine may reflect increased cellular proliferation or stress responses. These patterns are commonly observed in inflammatory conditions, toxin exposure, or metabolic disease states.

### 4. Pathway Relationships

Methionine → (transsulfuration) → Cysteine → (with glutamate) → Glutathione represents a key downstream relationship. Pyruvate connects these pathways to glycolysis and TCA cycle, serving as an integration point. Homogentisic acid (tyrosine catabolism) and putrescine represent parallel pathways that may respond to similar upstream regulators.

The convergence of sulfur amino acid metabolism with antioxidant systems (via glutathione and ascorbate) suggests a coordinated response to cellular stress.

---
